Mucosa-associated lymphoid tissue lymphoma: a perspective on current and future therapeutic strategies

Bibliography

• SWöhrer, BKiesewetter, JFischbach, et al. Retrospective comparison of the effectiveness of various treatment modalities of extragastric MALT lymphoma: a single-center analysis. Ann Hematol 2014;93:1287-95
   PubMed Web of Science ®Google Scholar
• PGIsaacson, AChott, SNakumura, et al. Extranodal marginal cell lymphoma of mucosa-associated tissue (MALT lymphoma). In: SHSwerdlow, ECampo, NLHarris, et al. WHO classification of tumours of the haematopoietic and lymphoid tissues. IARC; Lyon: 2008. p. 214-19
   Google Scholar
• MStolte, EBayerdörffer, AMorgner, et al. Helicobacter and gastric MALT lymphoma. Gut 2002;50(Suppl 3):III19-24
   PubMedGoogle Scholar
• WFischbach, MEGoebeler-Kolve, BDragosics, et al. Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series. Gut 2004;53:34-7
   PubMed Web of Science ®Google Scholar
• AAvilés, MJNambo, NNeri, et al. Mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach: results of a controlled clinical trial. Med Oncol 2005;22:57-62
   PubMed Web of Science ®Google Scholar
• RWTsang, MKGospodarowicz, MPintilie, et al. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol 2003;21:4157-64
   PubMed Web of Science ®Google Scholar
• ARuskoné-Fourmestraux, WFischbach, BMAleman, et al. EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut 2011;60:747-58
   PubMed Web of Science ®Google Scholar
• QTLe, SMEulau, TIGeorge, et al. Primary radiotherapy for localized orbital MALT lymphoma. Int J Radiat Oncol Biol Phys 2002;52:657-63
   PubMed Web of Science ®Google Scholar
• PLZinzani, VStefoni, GMusuraca, et al. Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma. Cancer 2004;100:2190-4
   PubMed Web of Science ®Google Scholar
• GJäger, PNeumeister, RBrezinschek, et al. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with caldribine: a phase II study. J Clin Oncol 2002;20:3872-7
   PubMed Web of Science ®Google Scholar
• ASalar, EDomingo-Domenech, CEstany, et al. Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type. Cancer 2009;115:5210-17
   PubMed Web of Science ®Google Scholar
• PHammel, CHaioun, MTChaumette, et al. Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression. J Clin Oncol 1995;13:2524-9
   PubMed Web of Science ®Google Scholar
• GPapaxoinis, GFountzilas, DRontogianni, et al. Low-grade mucosa-associated lymphoid tissue lymphoma: a retrospective analysis of 97 patients by the Hellenic Cooperative Oncology Group (HeCOG). Ann Oncol 2008;19:780-6
   PubMed Web of Science ®Google Scholar
• DHIsaacson P and Wright. Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma. Cancer 1983;52:1410-16
   Google Scholar
• MDreyling, CThieblemont, AGallamini, et al. ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol 2013;24:857-77
   PubMed Web of Science ®Google Scholar
• AJFerreri, SGovi, EPasini, et al. Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial. J Clin Oncol 2012;30:2988-94
   PubMed Web of Science ®Google Scholar
• LCerroni, NZöchling, BPütz, HKerl. Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma. J Cutan Pathol 1997;24:457-61
   PubMed Web of Science ®Google Scholar
• MLecuit, EAbachin, AMartin, et al. Immunoproliferative small intestinal disease associated with Campylobacter jejuni. N Engl J Med 2004;350:239-48
   PubMed Web of Science ®Google Scholar
• BKiesewetter, MRaderer. Antibiotic therapy in nongastrointestinal MALT lymphoma: a review of the literature. Blood 2013;122:1350-7
   PubMed Web of Science ®Google Scholar
• AJFerreri, MPonzoni, MGuidoboni, et al. Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a multicenter prospective trial. J Natl Cancer Inst 2006;98:1375-82
   PubMed Web of Science ®Google Scholar
• JJHan, TMKim, YKJeon, et al. Long-term outcomes of first-line treatment with doxycycline in patients with previously untreated ocular adnexal marginal zone B cell lymphoma. Ann Hematol 2014. [Epub ahead of print]
   Google Scholar
• TMKim, KHKim, MJLee, et al. First-line therapy with doxycycline in ocular adnexal mucosa-associated lymphoid tissue lymphoma: a retrospective analysis of clinical predictors. Cancer Sci 2010;101:1199-203
   PubMed Web of Science ®Google Scholar
• BGrünberger, WHauff, JLukas, et al. ‘Blind’ antibiotic treatment targeting Chlamydia is not effective in patients with MALT lymphoma of the ocular adnexa. Ann Oncol 2006;17:484-7
   PubMed Web of Science ®Google Scholar
• EChanudet, YZhou, CMBacon, et al. Chlamydia psittaci is variably associated with ocular adnexal MALT lymphoma in different geographical regions. J Pathol 2006;209:344-51
   PubMed Web of Science ®Google Scholar
• SGovi, GPDognini, GLicata, et al. Six-month oral clarithromycin regimen is safe and active in extranodal marginal zone B-cell lymphomas: final results of a single-centre phase II trial. Br J Haematol 2010;150:226-9
   PubMed Web of Science ®Google Scholar
• DAoki, SUeno, FKubo, et al. Roxithromycin inhibits angiogenesis of human hepatoma cells in vivo by suppressing VEGF production. Anticancer Res 2005;25:133-8
   PubMed Web of Science ®Google Scholar
• FGay, SVRajkumar, MColeman, et al. Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma. Am J Hematol 2010;85:664-9
   PubMed Web of Science ®Google Scholar
• RNiesvizky, DSJayabalan, PJChristos, et al. BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood 2008;111:1101-9
   PubMed Web of Science ®Google Scholar
• AJFerreri, MSassone, BKiesewetter, et al. High-dose clarithromycin is a feasible and active monotherapy for patients with relapsed/refractory extranodal marginal zone lymphoma [EMZL]: results from the “HD-K” phase II trial [abstract 442]. 19th congress of EHA; Milan; 2014
   Google Scholar
• GMartinelli, DLaszlo, AJFerreri, et al. Clinical activity of rituximab in gastric marginal zone non-Hodgkin’s lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol 2005;23:1979-83
   PubMed Web of Science ®Google Scholar
• AConconi, GMartinelli, CThiéblemont, et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood 2003;102:2741-5
   PubMed Web of Science ®Google Scholar
• ISLossos, DMorgensztern, MBlaya, et al. Rituximab for treatment of chemoimmunotherapy naive marginal zone lymphoma. Leuk Lymphoma 2007;48:1630-2
   PubMed Web of Science ®Google Scholar
• AJFerreri, MPonzoni, GMartinelli, et al. Rituximab in patients with mucosal-associated lymphoid tissue-type lymphoma of the ocular adnexa. Haematologica 2005;90:1578-9
   PubMed Web of Science ®Google Scholar
• MRaderer, GJäger, SBrugger, et al. Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma. Oncology 2003;65:306-10
   PubMed Web of Science ®Google Scholar
• JValencak, FWeihsengruber, KRappersberger, et al. Rituximab monotherapy for primary cutaneous B-cell lymphoma: response and follow-up in 16 patients. Ann Oncol 2009;20:326-30
   PubMed Web of Science ®Google Scholar
• MRaderer, SWohrer, BStreubel, et al. Activity of rituximab plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma. Oncology 2006;70:411-17
   PubMed Web of Science ®Google Scholar
• GJBen Simon, NCheung, PMcKelvie, et al. Oral chlorambucil for extranodal, marginal zone, B-cell lymphoma if mucosa-associated lymphoid tissue of the orbit. Ophthalmology 113:1209-13.2006
   PubMed Web of Science ®Google Scholar
• MTroch, BKiesewetter, WWillenbacher, et al. Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentose Tumortherapie. Haematologica 2013;98:264-8
   PubMed Web of Science ®Google Scholar
• EZucca, AConconi, DLaszlo, et al. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study. J Clin Oncol 2013;31:565-72
   PubMed Web of Science ®Google Scholar
• MLévy, CCopie-Bergman, AAmiot, et al. Rituximab and chlorambucil versus rituximab alone in gastric mucosa-associated lymphoid tissue lymphoma according to t(11;18) status: a monocentric non-randomized observational study. Leuk Lymphoma 2013;54:940-4
   PubMed Web of Science ®Google Scholar
• HLiu, HYe, ARuskone-Fourmestraux, et al. T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology 2002;122:1286-94
   PubMed Web of Science ®Google Scholar
• MLévy, CCopie-Bergman, CGameiro, et al. Prognostic value of translocation t(11;18) in tumoral response of low-grade gastric lymphoma of mucosa-associated lymphoid tissue type to oral chemotherapy. J Clin Oncol 2005;23:5061-6
   PubMed Web of Science ®Google Scholar
• GJäger, PNeumeister, FQuehenberger, et al. Prolonged clinical remission in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type treated with cladribine: 6 year follow-up of a phase II trial. Ann Oncol 2006;17:1722-3
   PubMed Web of Science ®Google Scholar
• MJRummel, NNiederle, GMaschmeyer, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013;381:1203-10
   PubMed Web of Science ®Google Scholar
• ASalar, EDomingo-Domenech, CPanizo, et al. First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial. Lancet Hematol; 2014;1:e104-e111
   Google Scholar
• BKiesewetter, MEMayerhoefer, JLukas, et al. Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma). Ann Hematol 2014;93:249-53
   PubMed Web of Science ®Google Scholar
• HLudwig, MBeksac, JBladé, et al. Current multiple myeloma treatment strategies with novel agents: a European perspective. Oncologist 2010;15:6-25
   PubMed Web of Science ®Google Scholar
• BKiesewetter, MTroch, WDolak, et al. A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma). Haematologica 2013;98:353-6
   PubMed Web of Science ®Google Scholar
• MRaderer, BKiesewetter, WWillenbacher, et al. A phase II study of rituximab plus lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma). Oral presentation at 19th congress of EHA; Milan; 2014
   Google Scholar
• AConconi, MRaderer, SFranceschetti, et al. Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group. Br J Haematol 2014;166:69-76
   PubMed Web of Science ®Google Scholar
• MRaderer, SWöhrer, BKiesewetter, et al. Antibiotic treatment as sole management of Helicobacter pylori-negative gastric MALT lymphoma: a single center experience with prolonged follow-up. Ann Hematol 2015. [ Epub ahead of print]
   Google Scholar
• SSuerbaum, PMichetti. Helicobacter pylori infection. N Engl J Med 2002;347:1175-86
   PubMed Web of Science ®Google Scholar
• AKGopal, BSKahl, Sde Vos, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 2014;370:1008-18
   PubMed Web of Science ®Google Scholar
• YWang, LLZhang, REChamplin, MLWang. Targeting Bruton’s tyrosine kinase with ibrutinib in B-cell malignancies. Clin Pharmacol Ther 2015; Epub ahead of print
   Google Scholar
• MTroch, CJonak, LMüllauer, et al. A phase II study of bortezomib in patients with MALT lymphoma. Haematologica 2009;94:738-42
   PubMed Web of Science ®Google Scholar
• AConconi, GMartinelli, ALopez-Guillermo, et al. Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the international extranodal lymphoma study group (IELSG). Ann Oncol 2011;22:689-952
   PubMed Web of Science ®Google Scholar